---
title: "Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299073443.md"
description: "Tuesday saw Vera stock experiencing a reversal in its performance, even after showcasing positive outcomes in its kidney disease treatment. This treatment stands as a competitor to products manufactured by prominent companies like Otsuka and Vertex. Despite the promising results, Vera's stock faced a setback in its trajectory. This shift occurred amidst escalating competition with Vertex, signaling potential challenges for Vera in the market."
datetime: "2026-09-15T15:26:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299073443.md)
  - [en](https://longbridge.com/en/news/299073443.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299073443.md)
generator: "portal-rs"
---

# Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened?

Tuesday saw Vera stock experiencing a reversal in its performance, even after showcasing positive outcomes in its kidney disease treatment. This treatment stands as a competitor to products manufactured by prominent companies like Otsuka and Vertex. Despite the promising results, Vera's stock faced a setback in its trajectory. This shift occurred amidst escalating competition with Vertex, signaling potential challenges for Vera in the market.

### Related Stocks

- [VERA.US](https://longbridge.com/en/quote/VERA.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [4578.JP](https://longbridge.com/en/quote/4578.JP.md)

## Related News & Research

- [Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug](https://longbridge.com/en/news/299800601.md)
- [Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria](https://longbridge.com/en/news/299770014.md)
- [Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuria](https://longbridge.com/en/news/299762830.md)
- [Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen](https://longbridge.com/en/news/299880191.md)
- [Otsuka says Phase 3 FUSION trial shows ulefnersen improves function and survival in FUS-ALS](https://longbridge.com/en/news/299762916.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**